Table 3.
MMP SNPs and development of COPD in Vlagtwedde/Vlaardingen (GOLD stage ≥ II)
| SNP | No COPD N (%) | COPD N (%) | P value | SNP | No COPD N (%) | COPD N (%) | P value | ||
|---|---|---|---|---|---|---|---|---|---|
| MMP1 G-1607GG | G | 295 (26.4) | 44 (24.7) | 0.845 | MMP9 rs6065912 | TT | 873 (77.0) | 145 (80.1) | 0.576 |
| G&GG | 565 (50.6) | 94 (52.8) | TC | 245 (21.6) | 18 (33.2) | ||||
| GG | 257 (23.0) | 40 (22.5) | CC | 16 (1.4) | 3 (1.7) | ||||
| MMP2 C-1306T | CC | 609 (52.8) | 103 (55.4) | 0.180 | MMP9 rs8113877 | TT | 408 (35.8) | 76 (40.6) | 0.137 |
| CT | 466 (40.5) | 65 (34.9) | TC | 559 (49.0) | 77 (41.2) | ||||
| TT | 77 (6.7) | 18 (9.7) | CC | 174 (15.2) | 34 (18.2) | ||||
| MMP12 Asn357Ser | AA | 1054 (93.1) | 171 (94.0) | 0.673 | MMP9 rs3918278 | GG | 1078 (94.7) | 177 (96.7) | 0.122 |
| AG | 78 (6.9) | 11 (6.0) | GA | 59 (5.2) | 5 (2.7) | ||||
| GG | 0 (0) | 0 (0) | AA | 1 (0.1) | 1 (0.6) | ||||
| MMP12 A-82G | AA | 812 (72.2) | 130 (71.4) | 0.831 | |||||
| AG | 281 (25.0) | 48 (26.4) | |||||||
| GG | 32 (2.8) | 4 (2.2) |